Priligy News and Research

RSS
Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories enters into definitive agreement to acquire Furiex

Furiex reports financial and operating results for third quarter 2013

Furiex reports financial and operating results for third quarter 2013

Menarini, Furiex enter license agreement to commercialize Priligy

Menarini, Furiex enter license agreement to commercialize Priligy

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio, Australian TGA reach agreement over Zertane submission plan

Premature ejaculation treatment market to reach over $1.3 billion by 2017

Premature ejaculation treatment market to reach over $1.3 billion by 2017

Furiex second-quarter 2010 revenues increase to $8.1M from $0.2M in second-quarter 2009

Furiex second-quarter 2010 revenues increase to $8.1M from $0.2M in second-quarter 2009

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

Priligy - new drug for premature ejaculation

Priligy - new drug for premature ejaculation

PPD reports 30% sequential increase in gross authorizations for first-quarter 2010

PPD reports 30% sequential increase in gross authorizations for first-quarter 2010

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.